You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer

Citation Tools

Article menu

Download PDFPDF

Poster Presentation
A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Urba W, Chmielowski B, Loo D, et al
A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer
Journal for ImmunoTherapy of Cancer 2015;3:P176. doi: 10.1186/2051-1426-3-S2-P176